CAR-T Cell Therapy Approved to Treat Adults With Certain Types of Large B-Cell LymphomaNalleyCatlin
[2]Ying Z,et al.Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021 Feb;10(3):999-1011. https://w...
The Food and Drug Administration (FDA) has approved a breakthrough cancer therapy known as CAR-T for use in adults with advanced lymphoma. The therapy uses a patient's own white blood cells, which are modified in a lab and re-trained to recognize specific markers on the surface of the ce...
编者按:2017年9月13日,《新英格兰医学杂志》在线发表(10月5日纸质版)“悲剧、坚持和机遇——CAR-T疗法的故事”(Tragedy, Perseverance, and Chance — The Story of CAR-T Therapy)。《NEJM医学前沿》邀请到美国南卡罗莱纳医科大学李子海教授撰写述评,解读CAR-T历史、进展和挑战。《知识分子》获授权转载。《NEJM医...
正是看中了CAR-T极具前景的治疗潜力,今年8月底,吉利德豪掷120亿美元将Kite收购,进军CAR-T领域。(相关阅读:吉利德发力:119亿美金并购CAR-T巨头Kite制药) 原文出处:Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First ...
UPDATED AUGUST 31 // The first T-cell therapy that uses chimeric antigen receptor (CAR) technology has been approved today by the US Food and Drug Administration (FDA), paving the way for the other products using this novel approach that are in development. "We're entering a new frontier ...
proofread Ok! The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
p>The FDA approved 46 new drugs last year, the highest total in more than two decades.doi:10.1038/nrd.2017.249MullardAsherNat Rev Drug DiscovNature Reviews Drug DiscoveryMullard A. Second anticancer CAR T therapy receives FDA approval. Nat Rev Drug Discov [Internet]. 2017;16(12):818-818. ...
2. Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma | Business Wire 3. Bill's Breyanzi® (lisocabtagene maraleucel) CAR T Cell Therapy Patient Story...
2. Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma | Business Wire 3. Bill's Breyanzi® (lisocabtagene maraleucel) CAR T Cell Therapy Patient Story...